Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: MorphoSys und I-Mab Biopharma Verkünden Freigabe für MOR202/TJ202 zum Beginn Klinischer Studien beim Multiplen Myelom in China

DGAP-News: MorphoSys und I-Mab Biopharma Verkünden Freigabe für MOR202/TJ202 zum Beginn Klinischer Studien beim Multiplen Myelom in China

0

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM

0

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET

DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET

0

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION

DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION

0

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN

DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt

DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio

0

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an

DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an

0

EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO

EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO

0

EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases

EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases

0

EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease

EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease

0

EQS-News: Evotec reports Q1 2024 results and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec reports Q1 2024 results and provides corporate update

EQS-News: Evotec reports Q1 2024 results and provides corporate update

0

EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024

EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024

0

EQS-News: Bayer and Evotec collaborate to advance precision cardiology: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Bayer and Evotec collaborate to advance precision cardiology

EQS-News: Bayer and Evotec collaborate to advance precision cardiology

0

EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results

EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results

0

EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

0

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth

0

EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

0

EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

0

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments

0

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024

0

EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer

EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer

0